Arrowhead Pharmaceuticals

This study tests a new medicine called ARO-APOC3 (plozasiran) in 75 adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder causing extremely high blood fats (triglycerides) that can lead to painful pancreatitis. Participants receive four shots of the drug or…

This study was designed to test the safety and effects of a drug called ARC-AAT in people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can cause liver and lung disease. Participants would have received multiple doses and needed liver biopsies before and af…

This study tests an injectable drug called plozasiran in 446 adults with severely high triglycerides (a type of fat in the blood). Participants receive either the drug or a placebo once every 3 months for a year. The goal is to see if the drug safely lowers triglyceride levels an…

This study tests a new medicine called plozsiran in 311 adults with severely high triglycerides, a type of blood fat that raises the risk of heart problems. Participants receive four shots over a year, either the drug or a placebo, to see if it safely lowers their fat levels. The…

This study aimed to test a new drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if ARC-520 could safely lower a key virus marker (HBsAg) in the blood. However, the study was withdrawn before any par…

This early-stage study tests a new drug, ARO-CFB, in healthy volunteers and people with a kidney disease called IgA nephropathy. The main goal is to check safety and how the drug moves through the body. Participants receive one or two doses of the drug or a placebo.

This study tests a new medicine called plozasiran, given as an injection every 3 months, to lower high triglycerides (a type of blood fat) in adults. About 1,456 people will receive either the drug or a placebo for a year. The goal is to see if the drug safely reduces triglycerid…